These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34404331)

  • 1. A clearer view on ovarian clear cell carcinoma.
    De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
    Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
    Itamochi H; Oishi T; Oumi N; Takeuchi S; Yoshihara K; Mikami M; Yaegashi N; Terao Y; Takehara K; Ushijima K; Watari H; Aoki D; Kimura T; Nakamura T; Yokoyama Y; Kigawa J; Sugiyama T
    Br J Cancer; 2017 Aug; 117(5):717-724. PubMed ID: 28728166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
    Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
    EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
    Gan M; Tai Z; Yu Y; Zhang C; Xu J
    PeerJ; 2023; 11():e14653. PubMed ID: 36721777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
    Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
    Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
    Fujiwara S
    Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Oda K; Hamanishi J; Matsuo K; Hasegawa K
    Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.
    Farah AM; Gu S; Jia Y
    Medicine (Baltimore); 2022 Sep; 101(37):e30666. PubMed ID: 36123851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
    Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
    J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future strategies for treatment of ovarian clear cell carcinoma.
    Ogasawara A; Sato S; Hasegawa K
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
    Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
    Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
    Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
    Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.
    Dong S; Yu F; Liu Y; Yu X; Sun X; Wang W; Wang Y
    Ginekol Pol; 2023; 94(10):792-798. PubMed ID: 36477777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
    Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
    Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
    Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
    Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
    Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
    Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.
    Takahashi K; Takenaka M; Kawabata A; Yanaihara N; Okamoto A
    Int J Clin Oncol; 2020 Mar; 25(3):425-431. PubMed ID: 31989349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CACNA1H restrains chemotherapy resistance in ovarian clear cell carcinoma cells by repressing autophagy.
    Shi H; Zheng L; Jiang X; Chen H
    Mol Genet Genomics; 2024 Aug; 299(1):77. PubMed ID: 39105964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.